MoonLake Immunotherapeutics (MLTX) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St indexes climb after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Guggenheim on 'Best Idea' Moonlake Immunotherapeutics (MLTX): 'We Continue To Anticipate Highly Positive Pivotal HS Readout Around Sept (2H)'
August 5, 2025 12:26 PM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $80.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).
The analyst comments "Key Message: Our key takeaways from MLTX's 2Q25 release are: (1) Highly-anticipated Phase III VELA results that evaluate sonelokimab (SLK; small nanobody with dual IL-17A/F targeting) in hidradenitis suppurativa (HS) remain on-track for "around" September. Last patient, last visit has occurred in VELA-2; VELA-1 is on-track to complete in August. Assuming ~4-6 weeks of data analysis, we think data are likely... More
